Overview

Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3

Status:
Enrolling by invitation
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
A long term safety study of amifampridine phosphate in patients with spinal muscular atrophy (SMA) Type 3.
Phase:
Phase 2
Details
Lead Sponsor:
Catalyst Pharmaceuticals, Inc.
Treatments:
3,4-diaminopyridine
4-Aminopyridine
Amifampridine